These results indicate that the p.Arg396Trp mutation modifies the binding dynamics of GATA2, affecting drug affinity and implying potential consequences for drug efficacy and therapeutic approaches in glioma treatment. This evidence concerns the gene GATA2 and central nervous system cancer.